08:00 AM EDT, 09/02/2025 (MT Newswires) -- Stoke Therapeutics ( STOK ) and Biogen (BIIB) said Tuesday that data from the phase 1/2a and open-label extension studies of zorevunersen supported the potential of the investigational drug to treat Dravet syndrome.

Across the studies, the drug showed "substantial and durable reductions" in major motor seizure frequency and continuing improvements in cognition, behavior, and quality of life atop standard anti-seizure regimens, the companies said.

Zorevunersen was generally well tolerated across all studies, with the ongoing phase 3 trial focused on assessing the efficacy, safety, and tolerability of the drug, they added.